William O’Neill, MD, and panelists Aditya Bharadwaj, MD, Alexandra Lansky, MD, and Norman Mangner, MD, discuss not only how to define high-risk percutaneous coronary intervention (HRPCI), but also how to predict outcomes and optimal revascularization strategies. Dr. Bharadwaj describes the characteristics of high-risk PCI patients. Dr. Lansky explains how two existing risk scores-- NCDR Cath PCI and BCIS CHIP-PCI—overestimate outcomes in Impella®-supported HRPCI patients. Dr. Mangner discusses the ongoing PROTECT IV randomized controlled trial. The panelists engage in insightful discussion and answer questions between presentations.

You must be logged in to view this content

Log in Sign up